Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT05754840 Not yet recruiting - Cancer Clinical Trials

CANnabinoids in Pediatric ONCology

CAN-PONC
Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

CANnabinoids in Pediatric ONCology is a randomized, double blind, adaptive clinical trial looking at the tolerability of cannabinoids in children with cancer across 3 Canadian children's hospitals.

NCT ID: NCT05754801 Not yet recruiting - Cancer Clinical Trials

Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

A randomized, double-blinded, placebo-controlled clinical trial using a Chinese Medicine 'Coriolus Versicolor for improving the quality of life of patients with advanced-stage cancer. Subjects will be randomized into a treatment group or placebo group for 6 months.

NCT ID: NCT05748704 Recruiting - Cancer Clinical Trials

Metabolic and Immunological Effects of a Modified Fasting Regimen in Cancer Patients

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

This is a single-arm prospective pilot study assessing the metabolic and immunologic effects of a modified fasting regimen in cancer patients with different cancer types and concomitant anticancer treatment.

NCT ID: NCT05746169 Recruiting - Cancer Clinical Trials

Discovering Cancer Risks From Environmental Contaminants and Maternal/Child Health

Start date: September 1, 2021
Phase:
Study type: Observational

The DREAM Cohort is a longitudinal observational study developed to enhance our understanding of how multiple exposures to environmental chemicals and pollutants across a diverse population of pregnant women and their offspring are linked to cancer risks. Because pregnancy induces multiple maternal hormonal and physiological changes that can increase cancer susceptibility to environmental chemical exposures, this study will focus on pregnancy as a period of particular vulnerability to toxic agents.

NCT ID: NCT05745038 Recruiting - Cancer Clinical Trials

A Single Arm Pilot Trial of a Social Network Intervention

SONATA
Start date: November 29, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to see if a social network support program (SOcial Networks to Activate Trust & Adherence or SONATA) is helpful for older individuals receiving cancer treatment. The SONATA program will last for about 4 months. There are a total of 6 coaching sessions. The first 5 sessions will be held approximately every 1 to 2 weeks. Session 6 or the final session will be held approximately 1 to 2 months after session 5. Each session will last for about 1 to 2 hours.

NCT ID: NCT05743491 Terminated - Cancer Clinical Trials

Yoga Versus Standard Care for Reducing Fatigue in Hispanic Cancer Survivors (YOCAS©®)

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

This is a phase II 2-arm randomized controlled trial comparing yoga (Yoga for Cancer Survivors, YOCAS©®) to standard care in reducing cancer-related fatigue in Hispanic cancer survivors. Survivors randomized to Arm 1 will receive Standard Care and Arm 2 will receive standard care plus a four-week YOCAS©® intervention where Hispanic survivors attend yoga sessions together. Investigators will acquire preliminary data on cancer-related fatigue, as well as, secondary data on other common side effects.

NCT ID: NCT05741242 Enrolling by invitation - Cancer Clinical Trials

Basket Trial of Neoantigen Synthetic Long Peptide Vaccines in Patients With Advanced Malignancy

Start date: November 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a basket trial of neoantigen synthetic long peptide vaccines in patients with advanced malignancy. Up to 20 subjects will be treated with the neoantigen synthetic long peptide vaccines.

NCT ID: NCT05739305 Recruiting - Cancer Clinical Trials

Death Certificate Analysis at Colombian Orinoquia: A Retrospective Observational Trial.

Start date: July 1, 2023
Phase:
Study type: Observational

By hospital mortality, the health of a population is identified. Death certificates are a valuable tool in establishing causes of death. The objective will be to analyze the main causes of death in hospitalized patients by population groups of interest. A retrospective observational study will be carried out, by analyzing the death databases of the Hospital Departamental of Villavicencio from January 2012 to May 2022. The records will be exported to Excel for review and debugging. Demographic variables and causes of death will be analyzed. The categorical variables will be described in frequency and proportion; the quantitative ones will be defined in their central distribution and dispersion. For comparison, the Chi-square and Mann-Whitney test will be performed according to the characteristics of the outcome studied. It is expected to identify the main causes of death in the groups of interest (adults, maternal, infants, fetal and non-fetal, congenital malformations) and their characteristics.

NCT ID: NCT05736731 Recruiting - Cancer Clinical Trials

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

EVEREST-1
Start date: April 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A*02 expression. The main questions this study aims to answer are: - Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients - Phase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: - Enrollment and Apheresis in BASECAMP-1 (NCT04981119) - Preconditioning Lymphodepletion (PCLD) Regimen - A2B530 Tmod CAR T cells at the assigned dose

NCT ID: NCT05734963 Recruiting - Cancer Clinical Trials

ORganoid GeneratioN Study for Cancer

ORIGINS
Start date: April 4, 2022
Phase:
Study type: Observational

ORIGINS - a multi-site sample collection study to establish patient-derived pre-clinical models for cancers